ArticleJAAD international2026
In vivo molecular skin fluorescence imaging for noninvasive assessment of atypical nevi and melanoma: A validation trial.
Article in JAAD international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current visual assessments and assistive technologies for melanoma detection primarily focus on detecting morphological changes, often requiring invasive biopsies for confirmation. Objective: To determine the efficacy of skin fluorescent imaging (SFI), a novel noninvasive technology for detection of αvβ3 integrin in the tumor microenvironment, for discrimination of benign from malignant melanocytic lesions. Methods: A prospective validation trial evaluated 240 clinically suspicious cutaneous pigmented lesions prior to biopsy in 6 academic and community dermatology clinics in California, Utah, and Oregon. Results: The distribution of lesions included 99 (41%) lesions without dysplasia, 59 (25%) nevi with low-grade dysplasia, 51 (21%) nevi with high-grade dysplasia, 20 (8.3%) melanoma in situ, and 11 invasive melanomas (4.6%). SFI cutoff scores of 5 and 7 demonstrated sensitivities of 93% and 87% and specificities of 77% and 91%, respectively, for discrimination of lesions with no or low-grade dysplasia from those with high-grade dysplasia or melanomas. The area under the receiver operating characteristic curve was 0.907 (95% CI 0.864-0.951, Limitations: This was a single-arm trial. Conclusions: SFI demonstrated high sensitivity and specificity for discriminating low-risk from high-risk lesions, representing a promising approach to enhance evaluation of clinically concerning pigmented lesions and reduce unnecessary biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.